Trial Profile
Safety and tolerability of second-generation encapsulated cell (EC) biodelivery of nerve growth factor (NGF), NGC 0295, in patients with Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2020
Price :
$35
*
At a glance
- Drugs EC NGF (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Gloriana Therapeutics; NsGene
- 01 Dec 2019 According to a Gloriana Therapeutics company website, NsGene has changed its name to Gloriana Therapeutics.
- 01 Dec 2015 New trial record